| 5-HT5A — Serotonin Receptor 5A |
|---|
| Gene | HTR5A |
| UniProt ID | [P47864](https://www.uniprot.org/uniprotkb/P47864/entry) |
| PDB ID | None determined |
| Molecular Weight | 42 kDa (357 aa) |
| Subcellular Localization | Cell membrane, plasma membrane |
| Protein Family | Serotonin receptors (Class A, GPCR) |
| Signal Transduction | Gi/o-coupled, inhibits adenylyl cyclase |
The 5-HT5A receptor is a Gi/o protein-coupled serotonin receptor that inhibits adenylyl cyclase, reducing intracellular cAMP production. It is one of the least characterized serotonin receptor subtypes in the human brain, yet it plays important roles in modulating circadian rhythm, sleep-wake cycles, neuronal excitability, and cognitive processes[@grailhe2002][@wang2007].
¶ Gene and Protein Structure
The HTR5A gene is located on chromosome 7q36.3 and encodes a 357-amino acid protein. The gene structure is relatively simple compared to other serotonin receptor subtypes, with a single coding exon. This makes it resistant to alternative splicing events that generate multiple isoforms in other 5-HT receptor families.
5-HT5A has the typical 7-transmembrane domain structure characteristic of Class A GPCRs:
- N-terminal extracellular domain — Contains glycosylation sites
- Seven transmembrane helices (TM1-TM7) — Form the ligand-binding pocket
- Conserved motifs:
- DRY motif at the intracellular end of TM3 (Arg)
- NPxxY motif in TM7
- C-terminal intracellular domain — Relatively short compared to other 5-HT receptors
The receptor may exist as both monomers and dimers on the cell surface, with dimerization potentially affecting ligand binding kinetics and signaling properties.
The 5-HT5A receptor plays a crucial role in sleep architecture[@wang2007]:
- Sleep induction: Activation of 5-HT5A receptors promotes sleep onset and increases total sleep time
- Sleep consolidation: The receptor helps synchronize sleep-wake cycles through interactions with the suprachiasmatic nucleus
- REM sleep modulation: Evidence suggests 5-HT5A modulates REM sleep patterns
- Circadian rhythm: Receptor expression shows circadian variation, peaking during sleep-relevant hours
In hippocampal and cortical circuits, 5-HT5A receptors modulate[@badelec2021]:
- Learning and memory: Receptor activation influences hippocampal-dependent learning tasks
- Synaptic plasticity: Modulates long-term potentiation (LTP) and long-term depression (LTD)
- Neuronal excitability: Regulates firing patterns in pyramidal neurons
- Working memory: Contributes to prefrontal cortical function
Recent evidence suggests 5-HT5A has neuroprotective properties[@sah2022]:
- Oxidative stress response: Receptor activation can enhance antioxidant defenses
- Anti-apoptotic signaling: Couples to PI3K/Akt pathway promoting cell survival
- Calcium homeostasis: Modulates intracellular calcium dynamics
- Mitochondrial function: Influences mitochondrial viability in neurons
5-HT5A receptors are implicated in Alzheimer's disease pathophysiology:
- Sleep disturbances: Common early AD symptom linked to 5-HT5A dysfunction
- Circadian rhythm disruptions: Altered receptor expression in AD brains
- Cognitive decline: Receptor modulation affects memory circuits
- Beta-amyloid interactions: Potential cross-talk with amyloid pathology
- Neuroinflammation: Serotonergic modulation affects microglial activation
In PD, 5-HT5A may play roles in:
- Non-motor symptoms including sleep dysfunction
- Levodopa-induced dyskinesias
- Mood disorders (depression, anxiety)
- Cognitive impairment
Depression and Anxiety: Genetic variants in HTR5A have been associated with major depressive disorder and anxiety disorders[@monckton2020].
Schizophrenia: Some studies link 5-HT5A polymorphisms with schizophrenia susceptibility.
Migraine: The receptor is expressed in trigeminal pain pathways, suggesting a role in migraine pathophysiology.
5-HT5A represents an underexplored therapeutic target:
| Drug/Compound |
Stage |
Indications |
| AS-2674723 |
Preclinical |
Sleep disorders, migraine |
| SB-699551 |
Preclinical |
Cognitive enhancement |
| Various antagonists |
Research |
CNS disorders |
- Brain penetration: Achieving sufficient CNS exposure
- Selectivity: Avoiding activity at other serotonin receptors
- Dosing: Balancing efficacy with side effects
- Biomarkers: Lack of validated patient selection markers
- Insomnia and sleep-wake disorders
- Alzheimer's disease (cognitive symptoms)
- Migraine prophylaxis
- Depression (treatment-resistant)
- Cognitive impairment
| Brain Region |
Expression Level |
| Hippocampus |
High |
| Cerebral cortex |
Moderate-High |
| Hypothalamus |
Moderate |
| Suprachiasmatic nucleus |
High |
| Dorsal raphe nucleus |
Low-Moderate |
| Cerebellum |
Low |
5-HT5A couples primarily to Gi/o proteins:
- Inhibition of adenylyl cyclase → Decreased cAMP
- Activation of GIRK channels → Hyperpolarization
- PI3K/Akt pathway → Pro-survival signaling
- MAPK/ERK pathway — Cell growth and differentiation
- Calcium modulation — Through PLC inhibition
Common HTR5A polymorphisms include:
- rs6293 (A-42G): Affects promoter activity
- rs729755: Associated with neuropsychiatric phenotypes
- rs1800044: Coding variant with functional implications
These variants have been studied in:
- Major depressive disorder
- Bipolar disorder
- Schizophrenia
- Alzheimer's disease
- Parkinson's disease
Key areas for future research include:
- Structure determination: Crystal/Cryo-EM structure of 5-HT5A
- Substrate identification: Discovering downstream signaling effectors
- Animal models: Knockout/knockin models for function
- Biomarkers: Developing target engagement biomarkers
- Clinical trials: Translating preclinical findings
- Noda et al., 5-HT5A receptor expression in brain (2005)
- Yamazaki et al., 5-HT5A and neuronal function (2014)
- Kohen et al., 5-HT5A receptor structure (2001)
- Liu et al., 5-HT5A signaling mechanisms (2011)
- Nelson et al., 5-HT5A pharmacology (2013)
- Grailhe et al., 5-HT5A expression in brain regions (2002)
- Wang et al., 5-HT5A and sleep regulation (2007)
- Badelec et al., 5-HT5A in hippocampal learning (2021)
- Sah et al., 5-HT5A neuroprotection (2022)
- Monckton et al., 5-HT5A genetic variants (2020)